Turning scientific discoveries into better treatments. 

The University of Queensland Diamantina Institute (UQDI) is a biomedical research institute of The University of Queensland.  Our research focus is the convergence of clinical and basic science, in translational research on cancer and disorders of immune regulation. This is exemplified by the research of the Institute Head, Professor Ian Frazer, whose work lead to world’s first cervical cancer vaccine.  The Institute currently has approximately 200 researchers, students and support staff. 

The University of Queensland Diamantina Institute is located at Princess Alexandra Hospital, Queensland’s leading teaching hospital, and adjacent to the main University campus at St Lucia.  Our location on the Hospital campus brings together strong clinical interactions and world-class facilities that enable researchers to be at the forefront of their fields. Our researchers focus their efforts on turning their scientific discoveries into better treatments for diseases including a variety of cancers, osteoporosis, arthritis and other autoimmune diseases. 

The ARVEC (Arrayed Retroviral Expression Cloning) facility at UQDI, is a full service high-throughput screening facility offering assay development, functional screening and bioinformatic analysis. In addition to our involvement in the RNAi Global network, we have established a unique arrayed lentiviral expression library of currently >17,000 open reading frames for gain-of-function screens.  This facility is available to the wider research community.  For more information see our website: http://www.di.uq.edu.au/arvechcsfacility 

Institutional Contacts: 

Duka Skalamera PhD: Facility Manager 

Max Ranall: assay development and siRNA specialist 

Email: di.arvec@uq.edu.au 

RNAi Global Principal Investigators:  

Brian Gabrielli PhD. 

Tom Gonda PhD.